Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

In its news release, Moderna said its mRNA vaccine is the first RSV shot to come in a pre-filled syringe and says that will save time for health-care workers and reduce any errors in administering it.

In its news release, Moderna said its mRNA vaccine is the first RSV shot to come in a pre-filled syringe and says that will save time for health-care workers and reduce any errors in administering it.

Moderna said on Friday that Canada’s health regulator has approved its vaccine for respiratory syncytial virus (RSV) in adults 60 years and older, making it the country’s first authorized mRNA ...

Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to receive FDA ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...

But its financial fortunes have reversed since then due to declining demand for COVID-19 shots and slow uptake for an RSV ...

Moderna said it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the ...

Moderna's vaccine pipeline isn't likely to stop at flu, COVID, and RSV. A cytomegalovirus (CMV) vaccine candidate, mRNA-1647, is in the middle of a pivotal phase 3 trial that will read out results ...

TORONTO - Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won't be available until next year, ...

TORONTO — Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won't be available until next year, the company ...